ALIA-1758 / J&J, AbbVie - LARVOL DELTA

ENHANCED DELIVERY OF ANTI -PYROGLUTAMATE AMYLOID -BETA ANTIBODY, ALIA -1758, ACROSS THE BLOOD-BRAIN BARRIER VIA TFR -MEDIATED TRANSCYTOSIS (ADPD 2025) - P1 | "ALIA-1758 showed dose -dependent internalization of 3pE A β peptides in THP1 cells. Incubation with TfR ectod omain blocked internalization of A β peptides, thereby demonstrating TfR -dependent endocytosis. 3pE A β aggregates were internalized in IPSC -microglia by effector negative ALIA -1758 and microglia activation was not observed (measured by cytokine release)."

Alzheimer's Disease • CNS Disorders • GLI2

ALIA-1758-101: A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants (clinicaltrials.gov) - P1 | N=52 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2025 ➔ Apr 2025 | Trial primary completion date: Jan 2025 ➔ Apr 2025

Enrollment closed • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

AbbVie Completes Acquisition of Aliada Therapeutics (PRNewswire) - "AbbVie...announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie. Aliada's lead investigational asset is ALIA-1758...ALIA-1758 utilizes a novel blood-brain barrier (BBB)-crossing technology that enhances delivery of targeted drugs into the central nervous system (CNS)."

M&A • Alzheimer's Disease • CNS Disorders

AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline (PRNewswire) - "AbbVie...and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada's lead investigational asset utilizing this delivery technology, ALIA-1758, is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in development for the treatment of Alzheimer's disease...Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash, subject to certain customary adjustments. This transaction is expected to close in 4Q2024, subject to regulatory approvals and other customary closing conditions."

M&A • Alzheimer's Disease • CNS Disorders

ALIA-1758-101: A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: Aliada Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders

ALIA-1758-101: A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants (clinicaltrials.gov) - P1 | N=52 | Not yet recruiting | Sponsor: Aliada Therapeutics

New P1 trial • Alzheimer's Disease • CNS Disorders